QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
LON:DNL

Diurnal Group (DNL) Share Price, News & Analysis

GBX 27.30
0.00 (0.00%)
(As of 10/31/2022)
Today's Range
27.30
27.30
50-Day Range
27.30
27.30
52-Week Range
9.50
67.90
Volume
145,283 shs
Average Volume
483,617 shs
Market Capitalization
£46.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DNL stock logo

About Diurnal Group Stock (LON:DNL)

Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.

DNL Stock Price History

DNL Stock News Headlines

Da Nang Port Logistics JSC DNL
D&L Industries Inc
Forget NVIDIA, buy this $2 AI stock now…
This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.
D&L Industries Inc (DNL)
D&L Industries Inc.
Form 8.3 - Diurnal Group plc
Forget NVIDIA, buy this $2 AI stock now…
This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.
Diurnal Group plc (DNL.L)
AIQ boosted by deal to supply NFT marketplace in Hong Kong
Diurnal drops after losses nearly double and it seeks funding
Diurnal nosedives on need for further funding
Diurnal dips as bosses give investor presentation
Diurnal Group Ditest Clinical Trial Results Published
Diurnal Group PLC : Commercial launch of Efmody in the UK
Diurnal Group PLC : Business and Trading Update
See More Headlines
Receive DNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diurnal Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/15/2020
Today
4/19/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£4.68 million
Cash Flow
GBX 9.70 per share
Book Value
GBX 12.70 per share

Miscellaneous

Free Float
N/A
Market Cap
£46.33 million
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Richard Edward Bungay A.C.A. (Age 53)
    ACA, B.Sc., BSc, Interim CEO, CFO, Company Sec. & Director
    Comp: $338k
  • Prof. Richard Ross
    Chief Scientific Officer & Exec. Director
  • Mr. Stewart Jones
    Operations Director
  • Mr. John Porter MBBS
    Ph.D., Chief Medical Officer
  • Mr. David Bevan (Age 55)
    Chief Bus. Officer

DNL Stock Analysis - Frequently Asked Questions

How have DNL shares performed in 2024?

Diurnal Group's stock was trading at GBX 27.30 at the start of the year. Since then, DNL stock has increased by 0.0% and is now trading at GBX 27.30.
View the best growth stocks for 2024 here
.

How were Diurnal Group's earnings last quarter?

Diurnal Group plc (LON:DNL) announced its earnings results on Tuesday, September, 15th. The company reported ($4.30) EPS for the quarter, topping the consensus estimate of ($6.70) by $2.40.

What other stocks do shareholders of Diurnal Group own?
How do I buy shares of Diurnal Group?

Shares of DNL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:DNL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners